Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Haematologica

Volumn 101, Issue 7, 2016, Pages 821-829

  Verstovsek, Srdan ^a   Vannucchi, Alessandro M ^b   Griesshammer, Martin ^c   Masszi, Tamas ^d   Durrant, Simon ^e   Passamonti, Francesco ^f   Harrison, Claire N ^g   Pane, Fabrizio ^h   Zachee, Pierre ⁱ   Kirito, Keita ^j   Besses, Carlos ^k   Hino, Masayuki ^l   Moiraghi, Beatriz ^m   Miller, Carole B ⁿ   Cazzola, Mario ^o   Rosti, Vittorio ^p   Blau, Igor ^q   Mesa, Ruben ^r   Jones, Mark M ^s   Zhen, Huiling ^s   Li, Jingjin ^t   Francillard, Nathalie ^u   Habr, Dany ^t   Kiladjian, Jean Jacques ^v   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF FLORENCE   (Italy)

^c KLINIKUM MINDEN   (Germany)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF INSUBRIA   (Italy)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

ⁱ Stuivenberg General Hospital   (Belgium)

^j UNIVERSITY OF YAMANASHI   (Japan)

^k HOSPITAL DEL MAR   (Spain)

^l OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m HOSPITAL RAMOS MEJÍA   (Argentina)

ⁿ St Agnes Cancer Institute   (United States)

^o UNIVERSITY OF PAVIA   (Italy)

^p FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r MAYO CLINIC   (United States)

^s Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

^t NOVARTIS PHARMA AG   (Switzerland)

^u NOVARTIS PHARMA K K   (Japan)

^v INSERM   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2; LENALIDOMIDE; PEGINTERFERON; PIPOBROMAN; RUXOLITINIB; THALIDOMIDE; JANUS KINASE; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ALLELE; ARTHRALGIA; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BRAIN INFARCTION; BRAIN ISCHEMIA; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG CROSS TOLERANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEART INFARCTION; HEMATOCRIT; HEMATOLOGIC DISEASE; HERPES ZOSTER; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; MUSCLE SPASM; MYELOFIBROSIS; NON MELANOMA SKIN CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PHLEBOTOMY; PNEUMONIA; POLYCYTHEMIA VERA; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINA BLOOD VESSEL OCCLUSION; RHINOPHARYNGITIS; SPLEEN INFARCTION; SPLEEN SIZE; SPLENOMEGALY; THORAX PAIN; THROMBOCYTE COUNT; THROMBOPHLEBITIS; THROMBOSIS; TREATMENT RESPONSE; VEIN THROMBOSIS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; GENE FREQUENCY; GENETICS; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; MUTATION; TREATMENT OUTCOME;

ADULT; AGED; ALLELES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; HEMATOCRIT; HUMANS; JANUS KINASES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; POLYCYTHEMIA VERA; PROTEIN KINASE INHIBITORS; PYRAZOLES; TREATMENT OUTCOME;

EID: 84977123244     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2016.143644     Document Type: Article

References (17)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
2. Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol. 2014;93(12):1965-1976.
3. Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012;30(24):2995-3001.
4. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
5. Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778-4781.
6. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33.
7. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol. 1997;34(1):17-23.
8. Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29(29):3907-3913.
9. Alvarez-Larran A, Pereira A, Cervantes F, et al. Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood. 2012;119(6):1363-1369.
10. JAKAFI® (ruxolitinib) [package insert]. Wilmington, DE: Incyte Corporation. December 2014.
11. JAKAVI® (ruxolitinib) [package insert]. Horsham, West Sussex, United Kingdom: Novartis. April 2015.
12. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426-435.
13. Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126(4):560-561.
14. Marchioli R, Finazzi G, Specchia G, Masciulli A, Mennitto MR, Barbui T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.
15. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105(7):2664-2670.
16. Passamonti F, Rumi E, Pietra D, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-1579.
17. Barosi G, Birgegard G, Finazzi G, et al. A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2010; 148(6):961-963.